BTIG Initiates Coverage On ArriVent BioPharma with Buy Rating, Announces Price Target of $45

Benzinga · 2d ago
BTIG analyst Justin Zelin initiates coverage on ArriVent BioPharma (NASDAQ:AVBP) with a Buy rating and announces Price Target of $45.